Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
PRECICE intramedullary nail in the treatment of adult leg length discrepancy

Cosic F, Edwards E

(2020), Injury, 51(4), 1091-6

DOI: 10.1016/j.injury.2020.03.004

Recalcitrant plunging ranulas: a new approach to salivary tissue localization using prostate-specific membrane antigen positron emission tomography

Chen F, Barber TW, Tudge S

(2020), ANZ J Surg, 90(11), e108-9

DOI: 10.1111/ans.15824

Use of a radiopharmaceutical multidose dispenser for positron emission tomography: Risk assessment and mitigation measures for infection prevention

Karanfilovska D, Martin R, Barton H, Yap KS, Cheng A

(2020), Infection, Disease and Health, 25(2), 101-6

DOI: 10.1016/j.idh.2019.12.003

A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia

Lickliter JD, Gan HK, Voskoboynik M, Arulananda S, Gao B, Nagrial A, Grimison P, Harrison M, Zou J, Zhang L, Luo S, Lahn M, Kallender H, Mannucci A, Somma C, Woods K, Behren A, Fernandez-Penas P, Millward M, Meniawy T

(2020), DRUG DES DEV THER, 14, 1177-89

DOI: 10.2147/DDDT.S243787

Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial

Ratnayake G, Reinwald S, Shackleton M, Moore M, Voskoboynik M, Ruben J, van Zelm MC, Yu D, Ward R, Smith R, Haydon A, Senthi S

(2020), INT J RADIAT ONCOL, 108(1), 150-6

DOI: 10.1016/j.ijrobp.2020.05.022

First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors

Geva R, Voskoboynik M, Dobrenkov K, Mayawala K, Gwo J, Wnek R, Chartash E, Long GV

(2020), CANCER-AM CANCER SOC, 126(22), 4926-35

DOI: 10.1002/cncr.33133

Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma

Yau WH, Ameratunga M

(2020), J Clin Pharm Ther, 45(5), 1172-4

DOI: 10.1111/jcpt.13112

Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials

Terbuch A, Tiu C, Candilejo IM, Scaranti M, Curcean A, Bar D, Estevez Timon M, Ameratunga M, Ang JE, Ratoff J, Minchom AR, Banerji U, de Bono JS, Tunariu N, Lopez JS

(2020), Clin Cancer Res, 26(18), 4805-13

DOI: 10.1158/1078-0432.CCR-20-0454

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

Ameratunga M, Braña I, Bono P, Postel-Vinay S, Plummer R, Aspegren J, Korjamo T, Snapir A, de Bono JS

(2020), Brit J Cancer, 123(12), 1730-6

DOI: 10.1038/s41416-020-01077-z

The kinase polypharmacology landscape of clinical PARP inhibitors

Antolin AA, Ameratunga M, Banerji U, Clarke PA, Workman P, Al-Lazikani B

(2020), SCI REP-UK, 10(1), 2585

DOI: 10.1038/s41598-020-59074-4

Metastatic melanoma presenting as intravenous tumour thrombus

Nguyen J, Clements W, McLean C, Haydon A, Moore M, Yap KS, Mar V, Shackleton M

(2020), J MED IMAG RADIAT ON, 64(6), 814-6

DOI: 10.1111/1754-9485.13019

Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass

Byron Y, Nott L, Shackleton M

(2020), Melanoma Res, 30(6), 625-7

DOI: 10.1097/CMR.0000000000000696

Parity reduces mammary repopulating activity but does not affect mammary stem cells defined as CD24 + CD29/CD49fhi in mice

Dall GV, Vieusseux J, Seyed-Razavi Y, Godde N, Ludford-Menting M, Russell SM, Ashworth A, Anderson RL, Risbridger GP, Shackleton M, Britt KL

(2020), BREAST CANCER RES TR, 183(3), 565-75

DOI: 10.1007/s10549-020-05804-1

Cognitive-communication difficulties following traumatic brain injury sustained in older adulthood: a scoping review

Shorland J, Douglas J, O'Halloran R

(2020), International Journal of Language and Communication Disorders, 55(6), 821-36

DOI: 10.1111/1460-6984.12560

What is it like to have your loved one with a severe brain injury come to rehabilitation? The experiences of significant others

Checklin M, Fernon D, Soumilas J, Stephens D

(2020), Disability and Rehabilitation, 42(6), 788-97

DOI: 10.1080/09638288.2018.1510042

An exploratory prospective study of the association between return to work/study and health and well-being outcomes after acquired brain injury

Schneider EJ, Lawlor K, Roberts E, McMahon K, Solomon L, Austrin N, Lannin NL

(2020), Journal of Clinical Practice in Speech Pathology, 22(1), 48-52

The therapeutic use of digital technology in psychosis

Bell IH, Lim MH, Thomas N

(2020), In: J. Badcock & G. Paulik (Eds.), A clinical introduction to psychosis: Foundations for clinical psychologists and neuropsychologists. Academic Press, London, 637-62

Being a scientist-practitioner in the field of psychosis: Experiences from voices clinics

Paulik G, Thomas N, Glasshouse E, Hayward M

(2020), In: J. Badcock & G. Paulik (Eds.), A clinical introduction to psychosis: Foundations for clinical psychologists and neuropsychologists. Academic Press, London, 615-36

The assessment of people with psychotic and bipolar disorders

Brand R, Thomas N, Murray G

(2020), In: M. Sellbom & J. Suhr (Eds.), Cambridge handbook of clinical assessment and diagnosis. Cambridge University Press, Cambridge

The association between pain type, cognition and complaint after mild traumatic brain injury in prospectively studied premorbidly healthy adults admitted to hospital

Anderson JFI

(2020), Neuropsychology, 34(1), 53-62

DOI: 10.1037/neu0000585

209 210 211 212 213